Komori
K Pharma (4896) · FactRestated

Large patient populations and unmet medical needs in central nervous system diseases

First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20252024: 120242025: 120252026: 12026
Same theme, other companies
Large Patient Base and Unmet Medical Needs in Central Nervous System DiseasesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「The global ALS patient population is estimated at approximately 330,000 and the domestic population at approximately 10,000. In Japan, the annual number of patients with subacute spinal cord injury is approximately 5,000, the number with chronic spinal cord injury is approximately 100,000 to 200,000, and the number of patients with cerebral infarction is approximately 1.3 million.」

    The company reiterates patient-population figures and unmet medical needs for ALS, spinal cord injury and cerebral infarction.
  2. FY2024RestatedAnnual report

    「The global ALS patient population is estimated at approximately 330,000 and the domestic population at approximately 10,000. In Japan, the annual number of patients with subacute spinal cord injury is approximately 5,000, the number with chronic spinal cord injury is approximately 100,000 to 200,000, and the number of patients with cerebral infarction is approximately 1.3 million.」

    The company explains unmet needs in its target areas by presenting patient-population figures for ALS, spinal cord injury and cerebral infarction.
  3. FY2023First statedAnnual report

    「The global ALS patient population is estimated at approximately 330,000 and the domestic population at approximately 10,000. In Japan, the annual number of patients with subacute spinal cord injury is approximately 5,000, the number with chronic spinal cord injury is approximately 100,000 to 200,000, and the number of patients with cerebral infarction is approximately 1.3 million.」

    The company describes the business foundation targeting areas with no established effective treatment by quantifying patient populations for ALS, spinal cord injury and cerebral infarction.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Large patient populations and unmet medical needs in central nervous system diseases | K Pharma,Inc. (4896) | Komori